

February 18, 2022

The South Carolina state motto is “While I breathe, I hope.” Over the past few years, we faced many challenges in the pandemic, but never lost hope, especially in South Carolina. I am a physician leader who prioritizes the needs of physicians and patients, and would like the opportunity to serve on the South Carolina Board of Medical Examiners, Board Member at Large, to give back to South Carolina.

I joined Medical University of South Carolina (MUSC) in 2014, where I am an Associate Professor of Neurology, Neuromuscular Division, and the Director of the Electromyography Laboratory. I am Board Certified in Neurology, Clinical Neurophysiology, and Autonomic Disorders. I have a busy clinical practice, and am active in clinical research and medical education.

Over the course of my tenure at MUSC, I have served on Faculty Senate and Faculty Council. On the national level, I served on the Myasthenia Gravis Foundation of America (MGFA) Board of Directors 2017-2021. As a member of the MGFA Medical Scientific Advisory Board Education Committee, I focused on patient and physician education, advocacy and outreach.

I work with multidisciplinary teams in healthcare and recognize the importance of quality control. I see the value of our physicians and irreplaceable health care practitioners, and want to provide them with engaging medical education opportunities to ensure best healthcare possible for South Carolinians.

I am a dedicated member of the professional community. My dedication, attention to detail and prior Board experience make me an excellent candidate for the SC Board of Medical Examiners. Please consider me for the position of Board Member At Large.

Katherine Ruzhansky, MD, MS

Katherine Ruzhansky M.D.,M.S.

ACADEMIC APPOINTMENTS

MEDICAL UNIVERSITY OF SOUTH CAROLINA, Charleston, SC

Associate Professor of Neurology

Assistant Professor of Neurology

Director of EMG Lab

Clinical Neurophysiology Fellowship Program Director EMG Track

2019-present

2014-2019

2014-present

2017-present

COLUMBIA UNIVERSITY MEDICAL CENTER, New York, NY

Adjunct Assistant Professor of Neurology

2014-2019

EDUCATION

ALBANY MEDICAL COLLEGE, Albany, NY

MD

2004-2008

GRADUATE COLLEGE OF UNION UNIVERSITY, Schenectady, NY

MS Health Systems Administration

2000-2005

UNION COLLEGE

BS cum laude Biology and Studio Fine Arts

8 year BS/MS/MD Program with Albany Medical College

2000-2004

POST GRADUATE TRAINING

COLUMBIA UNIVERSITY MEDICAL CENTER,

NEW YORK PRESBYTERIAN HOSPITAL, New York, NY

Peripheral Neuropathy Clinical Fellow

2013-2014

COLUMBIA UNIVERSITY MEDICAL CENTER,

NEW YORK PRESBYTERIAN HOSPITAL, New York, NY

Clinical Neurophysiology Fellow

2012-2013

YALE-NEW HAVEN HOSPITAL, New Haven, CT

Neurology Resident

2009-2012

STAMFORD HOSPITAL, Stamford, CT

Medicine Intern

2008-2009

BOARD CERTIFICATION

UNITED COUNCIL FOR NEUROLOGIC SUBSPECIALTIES

Autonomic Disorders (AD00226-16)

Recertified

2016

2020

AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY

Clinical Neurophysiology (57810)

2013

AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY

General Neurology (2494)

2012

LICENSURE

CONNECTICUT STATE MEDICAL LICENSE

2010-2015

Katherine Ruzhansky M.D.,M.S.

SOUTH CAROLINA MEDICAL LICENSE	2014-present
NEW YORK STATE LIMITED PERMIT	2013-2014
NEW YORK STATE MEDICAL LICENSE	2014-2018
FEDERAL DEA	2014-present
SC DHEC	2014-present
FL expert witness license (7468)	2019-2021

BOARD ELIGIBILITY

AMERICAN ASSOCIATION OF NEUROMUSCULAR & ELECTRODIAGNOSTIC MEDICINE
American Board of Electromyography and Clinical Neurophysiology

NATIONAL ORGANIZATION MEMBERSHIP AND LEADERSHIP

MYASTHENIA GRAVIS FOUNDATION OF AMERICA (MGFA)

MG Walk SC Medical Ambassador

National Board of Directors

MG Walk SC Medical Chair

Medical Scientific Advisory Board

Strategic Planning Committee

2018
2017-2022
2017
2015-present
2019

AMERICAN ACADEMY OF NEUROMUSCULAR AND ELECTRODIAGNOSTIC MEDICINE (AANEM)

2016-present

PEER REVIEWED PUBLICATIONS

The Adverse Event Unit (AEU): A novel metric to measure the burden of treatment adverse events.

Hehir MK, Conway M, Clark EM, Aronzon DB, Kolb N, Kolb A, Ruzhansky K, Sadjadi R, De Sousa EA, Burns, TM.

PloS One. 2022 Feb 17; 17 (2): e0262109

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): multicentre, randomised, placebo-controlled, phase 3 trial.

Howard JF, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shkarashvili R, Smilowski M, Guglietta A, Ulrichs P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R, and the ADAPT Investigator Study Group.

Lancet Neurol. 2021 Jul;20(7):526-536.

Telemedicine visits in myasthenia gravis: expert guidance and the myasthenia gravis core exam (MG-CE). Guidon AC, Muppidi S, Nowak RJ, Gupta JA, Hehir MK, Ruzhansky KM, Burton LB, Post D, Cutter G, Conwit R, Mejia NI, Kaminski HJ, Howard JF.

Muscle Nerve. 2021 Sep;64(3):270-276

Early Data on Long-Term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis: A 2-year Update From the Open-Label Extension of the NEURO-TTR Trial. Brannagan TH, Wang, AK, Coelho T, Cruz M, Polydefkis MJ, Dyck PJ, Plante-Bordeneuve V, Berk JL, Barroso F, Merlini G, Conceição I, Hughes SG, Kwok J, Jung SW, Guthrie S, Pollok M, Benson M, Gertz M, NEURO-TTR open-label extension investigators.

Eur J Neurol. 2020 Aug; 27(8):1374-1381.

Katherine Ruzhansky M.D.,M.S.

Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis.

Clifford KM, Hobson-Webb LD, Benatar M, Turns TM, Bertnett C, Silvestri NJ, Howard JF Jr, Visser A, Crum BA, Nowak R, Beekman R, Kumar A, **Ruzhansky K**, Chen IA, Pulley MT, Laboy SM, Fellman MA, Howard DB, Kolb NA, Greene SM, Pasnoor M, Dimachkie MM, Barohn RJ, Hehir MK. *Muscle Nerve*. 2019 Apr; 59(4): 404-410.

Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.

Hehir MK, Hobson-Webb LD, Benatar M, Barnett C, Silvestri NJ, Howard JF Jr, Howard D, Visser A, Crum BA, Nowak R, Beekman R, Kumar A, **Ruzhansky K**, Chen IA, Pulley MT, LaBoy SM, Fellman MA, Greene SM, Pasnoor M, Burns TM. *Neurology*. 2017. Sep 5;89(10):1069-1077

Assessing mNIS+7_{ionis} and International Neurologists' Proficiency in an FAP Trial.

Dyck PJ, Kincaid JC, Dyck PJB, Chaudhry V, Goyal NA, Alves C, Salhi H, Wiesman JF, Labeyrie C, Robinson-Papp J, Cardoso M, Laura M, **Ruzhansky K**, Cortese A, Brannagan TH 3rd, Khoury J, Khella S, Waddington-Cruz M, Ferreira J, Wang AK, Pinto MV, Ayache SS, Benson MD, Berk JL, Coelho T, Polydefkis M, Gorevic P, Adams DH, Plante-Bordeneuve V, Whelan C, Merlini G, Heitner S, Drachman BM, Conceição I, Klein CJ, Gertz MA, Ackermann EJ, Hughes SG, Mauermann ML, Bergemann R, Lodermeier KA, Davies JL, Carter RE, Litchy WJ. *Muscle Nerve*. 2017 Nov;56(5):901-911.

Amifampiridine phosphate (Fidapse®) is Effective and Safe in A Phase 3 Clinical Trial in LEMS.

Oh SJ, et al and LEMS Study Group. *Muscle Nerve*. 2016 May;53(5):717-25.

Editorial by concerned physicians: Unintended effect of the Orphan Drug Act on the potential cost of 3,4-diaminopyridine.

Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Cifaloni E, Cohen JA, Corse A, Crum BA, David WS, Dimberg E, Sousa EA, Donofrio PD, Dyck PJ, Engel AG, Ensrud ER, Ferrante M, Freimer M, Gable KL, Gibson S, Gilchrist JM, Goldstein JM, Gooch CL, Goodman BP, Gorelov D, Gospe SM Jr, Goyal NA, Guidon AC, Guptill JT, Gutmann L, Gutmann L, Gwathmey K, Harati Y, Harper CM Jr, Hehir MK, Hobson-Webb LD, Howard JF Jr, Jackson CE, Johnson N, Jones SM, Juel VC, Kaminski HJ, Karam C, Kennelly KD, Khella S, Khoury J, Kincaid JC, Kissel JT, Kolb N, Lacomis D, Ladha S, Larriviere D, Lewis RA, Li Y, Litchy WJ, Logigian E, Lou JS, MacGowen DJ, Maselli R, Massey JM, Mauermann ML, Mathews KD, Meriggioli MN, Miller RG, Moon JS, Mozaffar T, Nations SP, Nowak RJ, Ostrow LW, Pascuzzi RM, Peltier A, **Ruzhansky K**, Richman DP, Ross MA, Rubin DI, Russell JA, Sachs GM, Salajegheh MK, Saperstein DS, Scelsa S, Selcen D, Shaibani A, Shieh PB, Silvestri NJ, Singleton JR, Smith BE, So YT, Solorzano G, Sorenson EJ, Srinivasen J, Tavee J, Tawil R, Thaisethawatkul P, Thornton C, Trivedi J, Vernino S, Wang AK, Webb TA, Weiss MD, Windebank AJ, Wolfe GI. *Muscle Nerve*. 2016 Feb;53(2):165-8.

Causes of neuropathy in patients referred as 'idiopathic' neuropathy.

Farhad K, Traub R, **Ruzhansky KM**, Brannagan, TH 3rd.

Muscle Nerve. 2016 Jun;53(6):856-61.

Neuromuscular complications of hematopoietic stem cell transplantation.

Ruzhansky KM, Brannagan TH 3rd. *Muscle Nerve*. 2015 Oct; 52(4): 480-7.

Discordant Phenotype in Monozygotic Twins With Lys35Thr TTR Familial Amyloidotic Polyneuropathy.

Ruzhansky K, Scoon J, Weimer LH, Maurer MS, Berk JL, Brannagan TH 3rd.

J Clin Neuromuscul Dis. 2014 Sep; 16(1): 1-6

Intravenous Immunoglobulin for Treatment of Neuromuscular Disease.

Ruzhansky K, Brannagan TH 3rd. *Neurology Clinical Practice* 2013 Oct; 3 (5): 440-445.

PEER REVIEWER

eNeurologicalSci, Muscle and Nerve, Frontiers in Immunology

COURSE REVIEWER

Diagnosis and Treatment of Amyloid Disorders – Alnylam

December 2020

Katherine Ruzhansky M.D.,M.S.

FUNDED RESEARCH:

Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis Janssen. <i>Site Principal Investigator</i>	2021
EXPLORE MG 2 MgNet. <i>Site Principal Investigator.</i>	2021
Radicava, (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS). Mitsubishi Tanabe. <i>Site Co-Investigator.</i>	2020-present
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients with Generalized Myasthenia Gravis. UCB Pharma. <i>Site Co-Investigator.</i>	2020-2021
HEALEY ALS Platform Trial. Healey Center for ALS at Mass General. <i>Site Co-Investigator.</i>	2020-2021
MGFA Task Force for Standardization of MG Outcome Measures. Myasthenia Gravis Foundation of America (MGFA). <i>Principal Investigator of QI project.</i>	2019-present
Ra 101495 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Confirm Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Generalized Myasthenia Gravis – RAISE/RAISE XT. Ra/UCB Pharma. <i>Site Principal Investigator.</i>	2019-present
ALXN 1210 – MG 306. Ravulizumab in gMG. Alexion. <i>Site Principal Investigator.</i>	2019-present
Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis (DETERMINE). Corbus. <i>Site Principal Investigator.</i>	2019-2021
Alnylam TTRSC02-002 HELIOS-A. Alnylam. <i>Site Principal Investigator.</i>	2018-2019
Alexion Ecu-MG-303. Eculizumab in Pediatric MG. Alexion. <i>Site Principal Investigator</i>	2018-present
An Efficacy and Safety Study of ARGENX-113 in Patients with Myasthenia Gravis Who Have Generalized Muscle Weakness (ADAPT, ADAPT+) Argenx 113-1704 and 113-1705. Argenx. <i>Site Principal Investigator</i>	2018-2020

Katherine Ruzhansky M.D.,M.S.

Expanded Access Program for Inotersen (ISIS 420915) in Patients with Hereditary Transthyretin Amyloidosis (hATTR). IONIS/AKCEA. <i>Site Principal Investigator</i>	2018
Prospective Multicenter Observational Cohort Study of Comparative Effectiveness of Disease-Modifying Treatments for Myasthenia Gravis. PROMISE-MG <i>Site Principal Investigator. PCORI.</i>	2018-present
Mexiletine in Sporadic ALS (Mexiletine2). University of Washington. <i>Site Sub-investigator.</i>	2017-2018
Deep Phenotyping in ALS. Barrow Neurologic Institute/ALSA. <i>Site Sub-investigator.</i>	2017
A phase 2 Randomized, Double- Blind, Placebo controlled trial of IMO-8400 in Adult Patients with Dermatomyositis. Idera. <i>Site Principal Investigator.</i>	2016-2018
Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis. Synapse. <i>Site Principal Investigator</i>	2014-2015
A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ALN-TTR02 in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP). Alnylam. <i>Site Sub-investigator</i>	2013-2014
Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy. Ionis. <i>Site Sub-investigator</i>	2013 - 2017
Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CBX129801 (Ersatta™), Long-Acting Synthetic C-Peptide, in Type 1 Diabetes Mellitus Subjects with Mild to Moderate Diabetic Peripheral Neuropathy. Cebix. <i>Site Sub-investigator</i>	2013 - 2014
Randomized, multicenter, double-blind, placebo-controlled, parallel-group phase III study to investigate the efficacy, safety, and tolerability of 2 different doses of IgPro20 (subcutaneous immunoglobulin) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) – the PATH study. CSL-Behring. <i>Site Sub-investigator</i>	
ACT11917-ALCHEMILLA Multinational, multicenter, randomized double-blind, placebo-controlled, parallel-group study of efficacy and safety of SAR292833 administration for 4 weeks in patients with chronic peripheral neuropathic pain. Sanofi-Aventis. <i>Site Sub-investigator</i>	2012-2013
Phase 3, Multicenter, Double-blind, Placebo-controlled Randomized Discontinuation Study Followed by an Open-label Extension Period to Evaluate the Efficacy and Safety of Amifampridine Phosphate (3,4- Diaminopyridine Phosphate) in Patients with Lambert-Eaton Myasthenic Syndrome (LEMS). Biomarin.	2011-2013

Katherine Ruzhansky M.D., M.S.

Site Sub-investigator

NON-FUNDED RESEARCH

- Rituximab in anti-MUSK Myasthenia Gravis.** Retrospective multi-center chart review looking at patients with anti-MUSK MG who had undergone Rituximab treatment. MUSC. 2016-2017
Site Principal investigator
- Long Term EEG Monitoring for Inpatient Epilepsy Surgery Patients in Columbia Presbyterian Medical Center and Payer Mix. 2005
Mentor: W.A. Hauser, M.D. Gertrude Sergievsky Center for Neuroepidemiology.

POSTERS PRESENTED

- Patient and Physician Perspectives on Generalized Myasthenia Gravis.**
Katherine Ruzhansky, MD; Neelam Goyal, MD; Suraj Muley, MD; Tuan Vu, MD; Kyle Richardson, PhD; Deborah Gelin, MD
44th Annual Carrell Krusen Neuromuscular Virtual Symposium. February 24-25, 2022.
- Patient Burden of Generalized Myasthenia Gravis.**
Suraj Muley, MD; Deborah Gelin, MD; Johan Mohd Sani, MPA; Katherine Ruzhansky, MD
American Academy of Neuromuscular and Electrodiagnostic Medicine. October 13-16, 2021. Aurora, CO.
- Burden of Generalized Myasthenia Gravis for the patient perspective.**
Suraj Muley, MD; Deborah Gelin, MD; Johan Mohd Sani, MPA; Katherine Ruzhansky, MD
43rd Annual Carrell Krusen Neuromuscular Virtual Symposium. February 18-19, 2021
- The Adverse Event Unit (AEU): A novel metric to measure the burden of treatment adverse events.**
M Hehir, M Conaway, E Clark, D Aronson, N Kolb, A Kolb, K Ruzhansky, R Sadjadi, E De Sousa, T Burns
MGFA Scientific Session. American Academy of Neuromuscular and Electrodiagnostic Medicine. October 16, 2019. Austin, TX.
- PROMISE-MG: Prospective Multicenter Observational Cohort Study of Comparative Effectiveness of Disease-Modifying Treatments for Myasthenia Gravis: Preliminary Results**
P Narayanaswami, D Sanders, J Guptill, F Li, R Desai, J Venitz, K Bibeau, A Krueger, PROMISE-MG Study Group (multicenter)
MGFA Scientific Session. American Academy of Neuromuscular and Electrodiagnostic Medicine. October 16, 2019. Austin, TX.
- Thymectomy is not associated with clinical improvement in MuSK myasthenia gravis.**
K. Clifford, L Hobson-Webb, M Benetar, T Burns, C Bennett, N Silvestri, J Howard, A Visser, B Crum, R Nowak, R Beckman, A Kumar, K Ruzhansky, I Chen, M Pulley, S Laboy, M Fellman, N Kolb, S Greene, M Pasnoor, M Dimachkie, R Barohn, M Hehir. MGFA Scientific Session, American Academy of Neuromuscular and Electrodiagnostic Medicine. Washington, DC. October 10, 2018.
MGFA Scientific Session. American Academy of Neuromuscular and Electrodiagnostic Medicine. October 10-14, 2018. Washington, DC.
- Advancing Multidisciplinary ALS Clinic Toward a Center of Excellence.**
I Chen, D Adams, S Rublee, K Ruzhansky, S Nease, J Kurent.
ALS Association National Conference. November 2-4, 2016. San Diego, CA.
- Blinded Retrospective Analysis of Rituximab Treatment in Anti-MuSK Myasthenia Gravis.**

Katherine Ruzhansky M.D.,M.S.

M Hehir, L Hobson-Webb, R Nowak, NJ. Silvestri, C Barnett Tapia, JF Howard, MA
Fellman, A Visser, H Katzberg, **K Ruzhansky**, M Pulley, M Pasnoor, S Greene, M Benatar,
BA Crum, and TM Burns.

MGFA Scientific Session. American Academy of Neuromuscular and Electrodiagnostic Medicine.
September 14-18, 2016. New Orleans, LA.

Adequacy of a Polyneuropathy Score (mNIS+7) and Proficiency

of International Neurologists for Oligonucleotide Trials of Familial Amyloid Polyneuropathy.

PJ Dyck, JC Kincaid, PJB Dyck, V Chaudhry V, NA Goyal, C Alves, H Salhi, JF Wiesman, C Labeyrie, J Robinson-Papp, M Cardoso M, M Laura, **K Ruzhansky**, A Cortese, TH Brannagan 3rd, J Khoury, S Khella, M Waddington-Cruz, J Ferreira, AK Wang, MV Pinto, SS Ayache, MD Benson, JL Berk, T Coelho, M Polydefkis, P Gorevic, DH Adams, V Plante-Bordeneuve, C Whelan, G Merlini, S Heitner, BM Drachman, I Conceição, CJ Klein, MA Gertz, EJ Ackermann, SG Hughes, ML Mauermann, R Bergemann, KA Lodermeier, JL Davies, RE Carter, WJ Litchy.

Peripheral Nerve Society June 28-July 2, 2015. Quebec City, Quebec, Canada.

Combined Intra-arterial Abiciximab and Balloon Angioplasty for Acute Ischemic Stroke.

K Ruzhansky, G Bernardini, D Yavagal.

American Heart Association International Stroke Conference February 19-21, 2008. New Orleans, LA.

INVITED PRESENTATIONS – NATIONAL

Update in MG clinical trials.

MGFA Southeast Regional Conference.

Virtual. June 26, 2021.

Expert Perspectives on Clinical Cases in the Management of Myasthenia Gravis.

CME/ABIM MOC. Medscape. Virtual. June 24, 2021.

Amyloidosis – joint Grand Rounds with Dr. Daniel Judge (cardiology)

Grand Rounds. Medical University of South Carolina. June 3, 2021. Charleston, SC.

Best Practices in MG Care.

MDA Engage: Myasthenia Gravis Symposium. November 2, 2019. Durham, NC.

Myasthenia Gravis Treatment Landscape (plenary session).

Myasthenia Gravis Family Planning (breakout session).

MGFA National Conference. March 31-April 2, 2019. Atlanta, GA.

Peripheral Neuropathy and Radiculopathy

Association of Administrative Law Judges Annual Education Conference. October 31, 2018. Charleston, SC

Myasthenia Gravis and Disorders of the Neuromuscular Junction.

Peripheral Neuropathies.

Rock the MOC Continuing Medical Education Conference. October 7, 2018. Charleston, SC

Thinking about starting a family.

MGFA National Conference. April 15-17, 2018. Kansas City, KS.

Myasthenia Gravis and Disorders of the Neuromuscular Junction.

Peripheral Neuropathies.

Rock the MOC Continuing Medical Education Conference. November 12, 2017. Charleston, SC

Are you an MG Expert?

Katherine Ruzhansky M.D.,M.S.

Medically Refractory MG.

MGFA National Meeting. March 24-28, 2017. New Orleans, LA

Myasthenia Gravis: Neuromuscular Junction, what's your function?

Rutgers University Neurology Grand Rounds. March 8, 2017. New Brunswick, NJ

Indications for Electrodiagnostic Studies for Lumbar Disorders

Spine Care 2017 Evaluation & Management of Patients with Lumbar Disorders February 25, 2017. Charleston, SC

Myasthenia Gravis and Disorders of the Neuromuscular Junction.

Peripheral Neuropathies.

Rock the MOC Continuing Medical Education Conference. November 20, 2016. Charleston, SC

Myasthenia Gravis: Neuromuscular Junction, what's your function?

Grand Rounds. Medical University of South Carolina. May 12, 2016. Charleston, SC

Evaluation of Acute Weakness.

3rd Annual Update for the Primary Care Practitioner CME Conference. April 2016. Charleston, SC

Myasthenia Gravis, a Historical Perspective.

Low Country MGFA support group. March 19, 2016. Winston-Salem, NC.

Myasthenia Gravis and Disorders of the Neuromuscular Junction.

Rock the MOC Continuing Medical Education Conference. November 22, 2015. Charleston, SC

Myasthenia Gravis as a Chronic Illness.

Carolinas Chapter MGFA. November 6, 2015. Charleston, SC

Evaluation of Acute Weakness.

2nd Annual Update for the Primary Care Practitioner CME Conference. April 2015. Charleston, SC

Myasthenia Gravis Treatment Update.

Low Country MGFA Chapter. April 2015. Charleston, SC.

Neuromuscular Complications of Hematopoietic Stem Cell Transplant.

Grand Rounds. Medical University of South Carolina. February 20, 2014. Charleston, SC.

OTHER PRESENTATIONS

Greco-Roman Stone Disease." *American Institute of Physics. Renal Stone Disease 2. Vol.1049: 316-319*

2008

Mentor: M. Moran, MD

Conducted historical review in Greek and Roman understanding of the pathophysiology of urolithiasis.

"Frederik Ruysch's Fascination With Urolithiasis." *American Institute of Physics. Renal Stone Disease 2. Vol.1049: 311-315*

2008

Mentor: M. Moran, MD

Biographical research paper detailing Ruysch's study of urolithiasis.

"Female Anatomy Lessons." *Journal of Endourology.*

2007

Mentor: M. Moran, M.D.

Conducted a critical review of writings regarding anatomy, cross-referencing to feminist literature regarding early female academic output.

Presented at the World Congress of Endourology October 30-November 5, 2007

Katherine Ruzhansky M.D.,M.S.

"Financial Evaluation of Performing Ureteroscopy in Managed Care Environment." *Journal of Endourology*. 2007
Mentor: M. Moran, M.D.
Performed a retrospective review of a computerized database for the reimbursement range of payers in the Upstate New York market for the year, 2006.
Presented at the World Congress of Endourology October 30-November 5, 2007

AWARDS

APS. Fundamentals of Pain Management, A Primer for Residents and Fellows Grant Recipient. 2012

Katherine Ruzhansky M.D.,M.S.

COMMITTEES AND LEADERSHIP

MEDICAL UNIVERSITY OF SOUTH CAROLINA

MUSC Faculty Council	2020
MUSC Clinical Bylaws Subcommittee	2018-2019
MUSC Faculty Senate	2016-2019
Neurology Research Committee	2014-present
Clinical Neurophysiology IT Committee	2014-present
Clinical Neurophysiology Executive Committee	2014-present

YALE-NEW HAVEN HOSPITAL

Neuropathology Committee Director

Organize monthly interdepartmental series of resident case presentations. Working in conjunction with pathology and neurosurgery departments to develop neuropathology core curriculum. 2010-2012

Neuroradiology Committee Director

Organize weekly conferences with residents and attendings. Revising curriculum and making conferences theme based. Teaching new residents basics of emergency neuroradiology. 2010-2012

ALBANY MEDICAL COLLEGE

Evidence Based Medicine Committee Member

Attended monthly meetings to discuss possible improvements of the Evidence Based Medicine Course at Albany Medical College. 2004-2006

Student Council – Class Representative

Served on the Student Council dealing with projects related to student life 2004-2005

Financial Aid Committee Member

Attended monthly meetings of the Financial Aid Committee and discussed issues related to financing medical education at Albany Medical College. 2004-2005

PERSONAL

Languages: English, fluent written and spoken Russian.

Interests: Peripheral Neuropathy, Familial Amyloidotic Neuropathy, Myasthenia Gravis, Immune mediated myopathy.